Among patients with CAD, PTSD is associated with both incident and recurrent heart failure hospitalizations. Post-traumatic stress disorder (PTSD) is linked with incident and recurrent heart failure ...

Credit: Getty Images. Significant factors limit MDMA’s ability to be used in the treatment of post-traumatic stress disorder. Significant factors limit MDMA’s ability to be used in the treatment of ...

A biopharmaceutical company dedicated to psychedelic treatment announced last week that its clinical trial on MDMA-assisted therapy for post–traumatic stress disorder (“PTSD”) produced encouraging ...

Many people have interpreted as a setback the “no” vote by an advisory committee to the Food and Drug Administration on Lykos Therapeutics’ new drug application for MDMA-assisted psychotherapy for ...

For veterans battling post-traumatic stress disorder, feeling better is more than just scoring better in clinical measurements. A new study shows that these two metrics often align.

These data represent one of the largest clinical development programs to date for adults living with PTSD and a significant development in a therapy area that hasn’t seen a new approval for a ...

The results will be used to seek FDA approval of MDMA, also known as ecstasy, as a treatment for post-traumatic stress disorder. Treating post-traumatic stress disorder (PTSD) with a combination of ...

A web of altered neurochemical pathways and physical brain changes result in post-traumatic stress disorder, or PTSD. The interplay between cortisol dysregulation, heightened norepinephrine levels, ...

A new study using advanced deep-learning brain age estimation shows that World Trade Center responders with PTSD exhibit signs of accelerated brain aging.

Compass Pathways has navigated to another successful midphase readout, linking its psilocybin therapy and psychological support to improvements in post-traumatic stress disorder (PTSD) in a small ...

MDMA therapy uses regulated doses of MDMA alongside psychotherapy sessions to help treat certain psychiatric conditions. MDMA increases certain neurotransmitters, such as serotonin, in the brain.